| 2020 |
Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body J-J, Minisola S. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone. January 2020;130:115113. |
0 |
0 |
| 2021 |
Sutter T, Duboeuf F, Chapurlat R, Cortet B, Lespessailles E, Roux J-P. DXA body composition corrective factors between Hologic Discovery models to conduct multicenter studies. Bone. January 2021;142:115683. |
1 |
1 |
| 2021 |
Sutter T, Duboeuf F, Chapurlat R, Cortet B, Lespessailles E, Roux J-P. Response to “Utilising DXA for body composition research studies”. Bone. August 2021;149:115992. |
0 |
0 |
| 2020 |
Chapurlat R, Bui M, Sornay‐Rendu E, Zebaze R, Delmas PD, Liew D, Lespessailles E, Seeman E. Deterioration of cortical and trabecular microstructure identifies women with osteopenia or normal bone mineral density at imminent and long‐term risk for fragility fracture: a prospective study. J Bone Miner Res. May 2020;35(5):833-844. |
7 |
4 |
| 2020 |
Paccou J, Martignène N, Lespessailles E, Babykina E, Pattou F, Cortet B, Ficheur G. Gastric bypass but not sleeve gastrectomy increases risk of major osteoporotic fracture: French population‐based cohort study. J Bone Miner Res. August 2020;35(8):1415-1423. |
2 |
1 |
| 2022 |
Whittier DE, Samelson EJ, Hannan MT, Burt LA, Hanley DA, Biver E, Szulc P, Sornay-Rendu E, Merle B, Chapurlat R, Lespessailles E, Wong AKO, Goltzman D, Khosla S, Ferrari S, Bouxsein ML, Kiel DP, Boyd SK. Bone microarchitecture phenotypes identified in older adults are associated with different levels of osteoporotic fracture risk. J Bone Miner Res. March 2022;37(3):428-439. |
6 |
3 |
| 2022 |
Geusens P, Bevers MSAM, van Rietbergen B, Messina OD, Lespessailles E, Oliveri B, Chapurlat R, Engelke K, Chines A, Huang S, Saag KG, van den Bergh JP. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. June 2022;37(6):1136-1146. |
0 |
0 |
| 2023 |
Whittier DE, Samelson EJ, Hannan MT, Burt LA, Hanley DA, Biver E, Szulc P, Sornay-Rendu E, Merle B, Chapurlat R, Lespessailles E, Wong AKO, Goltzman D, Khosla S, Ferrari S, Bouxsein ML, Kiel DP, Boyd SK. A fracture risk assessment tool for high resolution peripheral quantitative computed tomography. J Bone Miner Res. September 2023;38(9):1234-1244. |
1 |
1 |
| 2000 |
Pothuaud L, Porion P, Lespessailles E, Benhamou CL, Levitz P. A new method for three-dimensional skeleton graph analysis of porous media: application to trabecular bone microarchitecture. J Microsc (Oxford). August 2000;199(pt 2):149-161. |
17 |
15 |
| 2007 |
Beaupied H, Lespessailles E, Benhamou C-L. Evaluation of macrostructural bone biomechanics. Joint Bone Spine. May 2007;74(3):233-239. |
15 |
15 |
| 2018 |
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240. |
29 |
24 |
| 2020 |
Lespessailles E, Chapurlat R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int. October 2020;31(10):1829-1834. |
0 |
0 |
| 2020 |
Body J-J, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. October 2020;31(10):1935-1942. |
0 |
0 |